The delivery of cystic fibrosis transmembrane conductance regulator (CFTR) to airway epithelia is a goal of many gene therapy strategies to treat cystic fibrosis. Because the native regulatory elements of the CFTR are not well characterized, the development of vectors with heterologous promoters of varying strengths and specificity would aid in our selection of optimal reagents for the appropriate expression of the vector-delivered CFTR gene. Here we contrasted the performance of several novel gene-regulatory elements. Based on airway expression analysis, we selected putative regulatory elements from BPIFA1 and WDR65 to investigate. In addition, we selected a human CFTR promoter region (z 2 kb upstream of the human CFTR transcription start site) to study. Using feline immunodeficiency virus vectors containing the candidate elements driving firefly luciferase, we transduced murine nasal epithelia in vivo. Luciferase expression persisted for 30 weeks, which was the duration of the experiment. Furthermore, when the nasal epithelium was ablated using the detergent polidocanol, the mice showed a transient loss of luciferase expression that returned 2 weeks after administration, suggesting that our vectors transduced a progenitor cell population. Importantly, the hWDR65 element drove sufficient CFTR expression to correct the anion transport defect in CFTR-null epithelia. These results will guide the development of optimal vectors for sufficient, sustained CFTR expression in airway epithelia.Keywords: gene transfer; lung; cystic fibrosis Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause cystic fibrosis, a multiorgan disease that affects the sinuses, lung, sweat glands, intestines, liver, pancreas, and reproductive tracts (1-3). However, most of the morbidity and mortality associated with the disease results from chronic bacterial infections and inflammation in the lung. Developing gene transfer vectors for efficient, safe, and effective therapeutic expression in the appropriate cell types of the airways is an important consideration in the treatment of cystic fibrosis.CFTR mRNA is present in low copy numbers (1-2 copies per cell) in nasal, tracheal, and bronchial epithelia (4, 5). Previous work in Cftr-null murine models showed that achieving as little as 5% of normal CFTR concentrations resulted in a much larger correction of the chloride transport defect (50% of normal), suggesting that modest levels of transgene expression may confer a significant therapeutic benefit (6). Conversely, CFTR overexpression in airway epithelia may cause protein mislocalization to the basal surface and an overall net decrease in chloride current (7). The entire suite of regulatory elements for the CFTR locus is unknown, but several regions have been identified that span several hundred kilobases (8-12), a size too large to package efficiently in standard viral vectors. Thus, a need exists for vectors with appropriate transgene expression levels in the airway.To that end, we sought to develop vectors c...